UCB and Oxford University announce new R&D partnership

New collaboration to develop research in immunology and neurology

20-Mar-2012 - United Kingdom

UCB Pharma and Oxford University agreed to collaborate on cutting-edge pharmaceutical research projects, enabling scientists from industry and academia to work together to develop medicines to treat serious diseases in immunology and neurology.

These combined resources and expertise will give the best possible chance of turning innovative research into new medicines for patients, an area identified as a priority in the recent government Strategy for UK Life Sciences.

Professor Sir John Bell (Regius Professor of Medicine at Oxford University and former president of the Academy of Medical Sciences) and David Willetts (Minister for Universities and Science) joined Roch Doliveux (Chief Executive, UCB and Chairman of the Innovative Medicines Initiative) and Ismail Kola (Executive Vice President and President of New Medicines™ UCB) at UCB to sign the agreement.

The Oxford-UCB partnership will be funded by a contribution of £3.6 million from UCB and will run over 3 years. A steering committee of UCB and Oxford University representatives will oversee the collaboration via regular meetings to scope out and monitor new projects. Between five and 10 projects will be selected for investigation over the course of the three-year agreement. 

Other news from the department science

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance